X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Americas

More Than 60% of Drug Safety Experts Plan To Use AI to Improve the Speed and Security of Adverse Event Case Processing

Content Team by Content Team
23rd March 2018
in Americas, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

New research conducted in partnership with Informa Engage / Pharma Intelligence reveals that 62% of drug safety experts have implemented or plan to implement Artificial Intelligence (AI) to improve adverse event processing.

The findings point to an industry-wide push for a faster, more accurate, and more secure approach to pharmacovigilance using new technologies.

The success of pharmacovigilance efforts hinges on the ability to spot risks early, manage them effectively, and comply with increasingly complex regulations. Drug safety teams view AI as a means to achieve this, and have already begun to explore its potential:

  • 27% have or plan to implement AI for quality assurance
  • 23% have or plan to implement AI for follow-up processing
  • 19% have or plan to implement AI for faster reporting

Andrea Charles, Editor, Custom Content, Informa Pharma Intelligence said, “Safety teams are under immense pressure to work quickly and accurately, but their biggest concerns are patient safety and the protection of their data. They need a robust approach to pharmacovigilance that allows them to work faster while maintaining a high standard of accuracy and security, which is why they are replacing and enhancing their systems with advanced technologies that are fit for the job.”

The research also reveals an industry-wide shift towards cloud-based systems to improve security. Almost 60% of respondents already have safety solutions in the cloud or are planning to move there within the next two years.

Bruce Palsulich, VP of safety product strategy for Oracle Health Sciences, said, “With the increase in adverse events reported, and the flat growth in resources to manage safety case processing, pharmacovigilance teams are under extreme pressure to do more with less. Fortunately, adverse event processing is becoming faster and smarter with the help of AI and the cloud. Both technologies are helping drug safety experts to improve quality and accuracy in the handling of the data they work with, and drive down their reporting costs. The time is ripe for wider adoption, and it’s encouraging to see the industry embrace new ways of working that will benefit them and the public.”

For this study, data was gathered from 153 professionals (director level and above) with titles including regulatory affairs, risk management, head of pharmacovigilance and adverse event case reporting, within pharmaceutical companies, CROs and sponsors from around the globe (North America, Europe, Asia Pacific, South America, Middle East and Africa). The data was gathered from November 2017 to December 2017.

On 22 March 2018 at 11:00 a.m. ET, Oracle Health Sciences and Pharma Intelligence will host a webcast to explore these trends in detail. Experts from both organizations will outline the forces behind the uptake of AI and cloud-based systems in the drug safety sector, and share insight into how these technologies will improve pharmacovigilance efforts. Click here for more information and to register for the live webcast.

Previous Post

Prothena Announces Global Neuroscience R&D Collaboration with Celgene for Novel Therapies for Patients with Neurodegenerative Diseases

Next Post

CPhI & P-MEC China 2018: Build lucrative pharma business partnerships in China

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post

CPhI & P-MEC China 2018: Build lucrative pharma business partnerships in China

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In